NextCure Inc at Needham Healthcare Conference Transcript
Good afternoon, everyone. It is my pleasure to introduce NextCure. NextCure is developing NC318, a Siglec-15 antibody that may be the next big thing in the field of immuno-oncology.
Great. Thank you, Gil. My name is Timothy Mayer and I am the Chief Operating Officer at NextCure. I would like to thank Needham for the invitation and the opportunity to present today and Gil for hosting this section.
This is our forward-looking statement. NextCure is focused on discovering and developing next-generation immunomedicines to treat cancer and other immune-related or other immune-mediated diseases by restoring normal immune function.
I would like to start by presenting our recent highlights, which are summarized in the 3 Ps: pipeline, platform and people. Our lead program, NC318, is a novel humanized monoclonal antibody that recognizes Siglec-15, or S15 as we like to call it. We will come back to this, but we presented top-line Phase 1 data at the SITC conference last
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
